Latest Articles

Publication Date
Why the Women’s Health Space Needs to Expand Beyond Reproductive Health - MedCity News

Why the Women’s Health Space Needs to Expand Beyond Reproductive Health MedCity News

Published: Oct. 27, 2025, 10:24 p.m.
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - TipRanks

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study TipRanks

Published: Oct. 27, 2025, 10:21 p.m.
EDAP TMS S.A. Advances HIFU Treatment Study for Rectal Endometriosis - TipRanks

EDAP TMS S.A. Advances HIFU Treatment Study for Rectal Endometriosis TipRanks

Published: Oct. 27, 2025, 9:42 p.m.
Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic - citybuzz -

Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic citybuzz -

Published: Oct. 27, 2025, 9:33 p.m.
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 9:13 p.m.
Monday's Health Report: What is endometriosis and how can it affect your life? - WBRZ

Monday's Health Report: What is endometriosis and how can it affect your life? WBRZ

Published: Oct. 27, 2025, 9:02 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 27, 2025, 7:50 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Yahoo Finance

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Yahoo Finance

Published: Oct. 27, 2025, 7:33 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 27, 2025, 7:33 p.m.
Is menstrual fluid ‘the most overlooked opportunity’ in women’s health? - University of Cincinnati

Is menstrual fluid ‘the most overlooked opportunity’ in women’s health? University of Cincinnati

Published: Oct. 27, 2025, 7:31 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!